Incubation Time of Acute Human Immunodeficiency Virus (HIV) Infection and Duration of Acute HIV Infection Are Independent Prognostic Factors of Progression to AIDS

Philippe Vanhems,1 Bernard Hirschel,2 Andrew N. Phillips,3 David A. Cooper,4 Jeanette Vizzard,4 Joelle Brassard,5 and Luc Perrin2

CONCISE COMMUNICATION

The severity and the duration of acute human immunodeficiency virus (HIV) infection (AHI) are associated with a faster rate of progression to AIDS, but the prognostic value of the length of incubation time of AHI (IncAHI), defined as the time between HIV infection and AHI, on progression to AIDS has not been assessed. We explored this issue prospectively in 70 individuals with documented AHI and a known date of HIV infection. The median IncAHI was 21.5 days (range, 5–70 days), and the median duration of AHI was 15.5 days (range, 3–67 days). The adjusted relative hazard of progression to AIDS or to a CD4+ count <200×10^3/mL was 4.23 (95% confidence interval [CI], 1.40–12.73; P = .01) for the patients with an IncAHI <21.5 days, compared with those with longer IncAHI, and was 3.53 (95% CI, 1.09–11.36; P = .03) for the patients with a duration of AHI >15.5 days, compared with those with shorter duration. Both IncAHI and duration of AHI were independent predictors of progression. This suggests that early pathogenic events before the onset of AHI influence the rate of HIV disease progression.

Acute human immunodeficiency virus type 1 (HIV-1) infection (AHI) is a heterogeneous syndrome [1, 2]. Patients with more severe symptoms during AHI and an AHI lasting >15 days tend to progress faster toward AIDS [3, 4]. Data on the prognostic value of the incubation of AHI (IncAHI), defined as the time between HIV infection and AHI, are lacking. The objective of this investigation was to determine whether the time from HIV infection until the onset of AHI is an independent factor of progression to AIDS or toward a CD4+ count <200×10^3/mL after adjustment for duration of AHI.

Methods

This prospective study included a total of 70 patients with AHI for whom a date of HIV infection was known. These patients are a subgroup of a larger cohort of Swiss and Australian individuals described in detail elsewhere [1]. This cohort was initiated to study the clinical features of AHI and the comparison of the rates of disease progression by severity of AHI. The patients selected for this investigation were those with symptomatic AHI and with a date of HIV exposure reported in the data-collection form. The onset of AHI was before the end of 1987 in 6 patients, between 1988 and 1991 in 19 patients, and between 1992 and December 31, 1995 in 45 patients. Patients were asked about the date of infection at the time they presented with symptoms of AHI. The number of sexual partners within the last year was 1 for 57 patients (81.4%), 2 for 5 patients (7.1%), and >2 for the remainder (11.4%). The presumed route of HIV infection was self-reported; a total of 47 individuals (67%) reported infection by unprotected homosexual intercourse, 6 (8.5%) by unprotected receptive oral sex, 11 by heterosexual intercourse (15.7%), 2 after syringe exchange (3%), 1 after blood transfusion (1.4%), and 3 by another route not reported. The

Received 10 November 1999; revised 18 April 2000; electronically published 19 June 2000.


Financial support: Swiss Federal Office of Public Health through funding of the Swiss HIV Cohort Study (project 256) and Swiss National AIDS Program (grant 3200.56.059.98). The National Centre in HIV Epidemiology and Clinical Research is supported by the Australian National Council on AIDS through the Commonwealth AIDS Research Grants Committee. Informed consent was obtained from patients.

Reprints or correspondence: Dr. Philippe Vanhems, Laboratoire d’Epidémiologie et de Santé Publique, Université Claude Bernard Lyon 1, 8, av. Rockefeller, 69373 Lyon Cedex 08, France (philipva@lyon-sud.univ-lyon1.fr).

The Journal of Infectious Diseases 2000;182:334–7
© 2000 by the Infectious Diseases Society of America. All rights reserved. 0022-1899/2000/18201-0046$02.00
serostatus of patients’ partners was available for 11 individuals. In 2 cases (3%), the partner had AIDS, and in 9 cases (13%) he was asymptomatic. The date of exposure was based on the patient’s best estimate. IncAHI was defined as the time elapsed between the date of HIV infection and the date of AHI onset. The clinical features of AHI were recorded on standardized collection forms in the 2 centers (in Geneva and Sydney) [1]. Clinical and laboratory follow-up procedures were similar in both centers [1]. The laboratory criteria of AHI were (1) the presence of p24 antigenemia (n = 58) in patients with negative or indeterminate EIA serology, (2) 2 bands on Western blots, one of which corresponded to the env gene (gp 160, gp 120, gp 41; n = 3) with a negative EIA serology, and (3) a negative HIV-1 EIA test followed by a positive HIV-1 EIA test within 6 months (median, 85 days; range, 4–188 days; n = 9). HIV infection was confirmed in all patients by Western blots. CD4+ cell counts were conducted in laboratories affiliated with either university center. The laboratories in Geneva and Sydney are national reference centers, and quality control testing is done regularly. T cell subsets were measured by flow cytometry in both locations.

Groups were compared by the χ² test or Fisher’s exact test for categorical variables and by Student’s t test for continuous variables after logarithmic transformation, if necessary. Multiple linear regression was used for calculate the association between IncAHI and duration of AHI, after adjustment for confounders. The endpoint was AIDS according to the 1993 definition by the Centers for Disease Control and Prevention or a first CD4+ count <200 × 10⁶/mL. Progression was calculated by the Kaplan-Meier method, with the onset of AHI as time 0 and censoring at the last visit or at June 30, 1995, to exclude the confounding effect of the use of highly active antiretroviral therapy. Comparison of survival distribution was based on the log-rank test. The Cox proportional hazard model was used to estimate the adjusted relative hazard (ARH) of disease progression. No patient was considered lost to follow-up, defined as 1 year without knowledge of vital status. P values <.05 were considered statistically significant. Analysis was conducted with SPSS version 6.0 (SPSS, Chicago).

Results

The patients, 91% of whom were men, had a mean age of 30.6 years. Thirty-one patients were from Geneva and 39 from Sydney. The mean IncAHI was 25.8 days, with a median of 21.5 days (range, 5–70 days), and did not differ by center (P = .15). The mean duration of AHI was 16.8 days, with a median of 15.5 days (range, 3–67 days). The most common symptoms at AHI were fever (91%), lethargy (84%), skin rash (76%), headache (69%), myalgia (67%), arthralgia (41%), and diarrhea (27%). No difference in symptom frequency or the proportion of hospitalized patients (23%) was observed according to IncAHI greater than or less than 21.5 days.

Adjusted regression analysis did not identify independent variables associated with IncAHI (P = .77 for duration of AHI; P = .33 for age; P = .50 for gender; P = .36 for route of infection; P = .17 for the center [Geneva vs. Sydney]).

The duration of follow up was 24.3 months for patients with IncAHI below the median (21.5 days; group 1) and 24.2 months for patients with IncAHI above the median (group 2; P = .9). Antiretroviral treatment was prescribed in a similar proportion in the 2 groups (P = 1.00) at AHI (48%) and during follow up (60% for group 1 and 51% for group 2; P = .47). The mean interval between AHI and the start of antiretroviral therapy was 6.2 months for group 1 and 5.5 months for group 2 (P = .84). The regimens prescribed at AHI for patients in group 1 was single nucleoside reverse transcriptase inhibitor for 15 patients (43%), a combination of 2 nucleoside reverse transcriptase inhibitors for 1 patient (6%), and a combination of nucleoside reverse transcriptase inhibitor and acyclovir for 1 patient (6%); the regimens prescribed at AHI in group 2 were a single nucleoside reverse transcriptase inhibitor for 15 patients (43%), a combination of nucleoside reverse transcriptase inhibitor and acyclovir for 1 patient (6%), and a combination of nucleoside reverse transcriptase inhibitor and nonnucleoside retrontranscriptase inhibitor for 1 patient (6%). The proportion of patients treated within 3 months after AHI was similar between the two centers (58% for Geneva and 41% for Sydney; P = .16), and the total duration of antiretroviral was also similar between the two centers (mean of 4.6 months for Geneva and mean of 4.1 months for Sydney; P = .5). The proportion of patients who received primary Pneumocystis carinii prophylaxis was similar in both groups (P = .32). A total of 13 patients in group 1 and 8 patients in group 2 reached the end point during the follow-up. Six AIDS events occurred in group 1 (2 chronic herpes simplex ulcerations >1 month, 2 cryptosporidiosis, 1 AIDS dementia complex, and 1 cytomegalovirus infection), and
Infection.

dence interval; IncAHI, incubation of acute human immunodeficiency virus (HIV)

Table 1. Adjusted relative hazard of progression to AIDS or to a CD4+ cell count <200 × 10^3/mL.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Adjusted relative hazard (95% CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>IncAHI &lt;21.5 days</td>
<td>4.23 (1.40–12.73)</td>
<td>.01</td>
</tr>
<tr>
<td>Duration of AHI &gt;15.5 days</td>
<td>3.53 (1.09–11.36)</td>
<td>.03</td>
</tr>
<tr>
<td>Antiretroviral treatment at AHI</td>
<td>0.28 (0.08–0.94)</td>
<td>.04</td>
</tr>
<tr>
<td>Primary Pneumocystis carinii pneumonia prophylaxis</td>
<td>0.50 (0.13–1.84)</td>
<td>.30</td>
</tr>
<tr>
<td>Route of HIV infection</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Homosexual intercourse vs. others</td>
<td>0.25 (0.02–2.16)</td>
<td>.20</td>
</tr>
<tr>
<td>Center (Geneva vs. Sydney)</td>
<td>0.40 (0.11–1.30)</td>
<td>.12</td>
</tr>
</tbody>
</table>

NOTE. All the variables of the table were in the model equation. Age was not associated with progression (P = .69) and not included in the model. Model characteristics: −2 log likelihood, 83.556; χ², 24.513; 6 df; P = .0004. CI, confidence interval; IncAHI, incubation of acute human immunodeficiency virus (HIV) infection.

2 AIDS events occurred in group 2 (1 Mycobacterium avium complex infection and 1 chronic herpes simplex ulceration >1 month). By use of the Kaplan-Meier analysis, the median of progression to AIDS or to a CD4+ cell count <200 × 10^3/mL was 3.82 years (95% confidence interval [CI], 3.13–4.50) in group 1 and 5.05 years (95% CI, 1.80–8.28) in group 2 (P = .03; figure 1). One patient received protease inhibitors 243 days after AHI for a period of 92 days; this individual was in group 1 and did not have AIDS during follow-up. Survival analysis without this patient remained unchanged. By use of the Kaplan-Meier method, the median of progression to AIDS or to a CD4+ cell count <200 × 10^3/mL was 3.55 years (95% CI, 2.93–4.17) for individuals with a duration of AHI greater than the median (15.5 days) and 5.04 years (95% CI, 4.30–5.78) for those with a duration of AHI less than the median (P = .005).

We calculated the ARH of progression using the proportional hazard model after adjustment for the length of AHI and for potential confounders (table 1). The multivariate model identified both IncAHI and duration of AHI as independent prognostic factors of disease progression. Similar analysis with IncAHI and AHI as continuous variables identified only a long IncAHI (AHR, 0.95; 95% CI, 0.91–0.99; P = .03) as protective effect on disease progression. Among patients free of antiretroviral treatment at AHI, the mean of CD4+ within 1 month after onset was 467/mL (SD, 271) for group 1 patients (n = 14) and 604/mL (SD, 228) for group 2 patients (n = 21; P = .12) and the mean of CD4+ at 2 months after onset was 637/mL (SD, 263) for group 1 patients (n = 19) and 695/mL (SD, 325) for group 2 patients (α; P = .52). The use of antiretroviral therapy at AHI had a protective effect in this observational cohort.

Discussion

The objective of this study was to identify the independent prognostic value of the IncAHI and duration of AHI. Previously, early prognostic studies were done mostly at the onset of AHI and/or at the time of HIV seroconversion, but few investigations of IncAHI have been conducted. The question of the validity of the reported date of HIV infection is central and was ascertained on 3 grounds. First, the information was collected prospectively, which reduced memory bias. Second, the duration between infection and the onset of AHI was similar to that in studies elsewhere [2, 5–8], in which IncAHI ranged from 1 to 8 weeks. For example, IncAHI lasted 11–28 days for Gaines et al. [5], 5–29 days (mean, 15 days) for Schacker et al. [2], 2–3 weeks for Quin [6], and 3–6 weeks for Clark et al. [7]. Third, our results are consistent with data obtained from healthcare workers who developed AHI after needle-stick injuries [9]. In that case, the IncAHI reported was 14–28 days for Marcus et al. [10], 25 days for Oksenhendler et al. [11], and 16 days for Pratt et al. [12]. Although we cannot have total confidence in individual measures of the IncAHI, we think it unlikely that lack of precision would bias our results. For a bias to occur, patients destined to progress faster toward AIDS would have to systematically recall a presumed date of infection that was later than the real date of infection. The occurrence of such a systematic error does not seem plausible to us.

IncAHI was associated with progression toward AIDS in our cohort independently of duration of AHI. Because this result was obtained among individuals who reached a small number of outcomes, confirmatory studies are needed with larger cohorts. Pedersen et al. showed that duration of acute HIV infection was associated with a faster progression to AIDS [3]. The rapid rate of disease progression observed in our cohort was related to the absence of asymptomatic HIV seroconverters. Our study was conducted among patients who, except for 1, received what is now regarded as suboptimal therapy, because no protease inhibitors were administered until the end of follow-up. This provided the opportunity to study the natural history of disease progression without the confounding factor of highly active antiretroviral therapy.

The present investigation suggests that initial pathogenetic mechanisms could influence the rate of disease progression, even before the onset of AHI. The mechanisms influencing the length of IncAHI are not well understood. Because no specific anti-HIV immune response can be measured during that period, differences in the replicative capacities of HIV, in the interaction of HIV and mucosal surfaces or in the reaction of the innate immune system to HIV, could presumably play a role [13]. A short IncAHI could mean the virus has faster access to the target cells. Investigations on the transition period between IncAHI and onset of AHI could yield essential information on the respective contribution of the viral replication [14] and immunological response [15] that determine the prognosis. The impact of virus replication and its relationship to host genetic factors also need to be investigated.

This study suggests both IncAHI and duration of AHI were associated with the prognosis. These results confirm the key place of early events on late prognosis of HIV infection.
Acknowledgments

We wish to thank B. Anderson, D. Baker, A. Beveridge, M. Bloch, N. Doong, C. Duncombe, R. Finlayson, V. Furner, B. Genn, J. Gold, J. Kidd, R. McFarlane, M. McMurchie, A. McNulty, H. Michelmore, A. Pethebridge, D. Quan, and M. Robertson (Sydney); J. Kaldor and the late B. Tindall, at the National Centre in HIV Epidemiology and Clinical Research (Sydney); and J. F. Balavoine, A. Christina, C. Junet, V. Sendersky, J. Wintsch (Geneva), and S. Kinloch-de Loës (London). The members of the Swiss HIV Cohort Study are M. Bateguay (co-chair of the scientific board), E. Bernasconi, Ph. Bürgisser, M. Egger, P. Erb (chairman of the “Laboratories” group), W. Fierz, M. Flepp (chairman of the “Clinics” group), P. Francioli (president of the Swiss HIV Cohort Study, Centre Hospitalier Universitaire Vaudois, CH-1011 Lausanne), H. J. Furrer, P. Grob, B. Hirschel (co-chair of the scientific board), L. Kaiser, B. Ledergerber, R. Lüthy, R. Malinverni, L. Matter, M. Opravil, F. Paccaud, G. Pantaleo, L. Perrin, W. Pichler, J.-C. Piffaretti, M. Rickenbach, P. Sudre, J. Schupbach, A. Telenti, and P. Vernazza.

References